Benefit–risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients

References

• StrandbergTEKolehmainenLVuorioAEvaluation and treatment of older patients with hypercholesterolemia: a clinical reviewJAMA2014312111136114425226479
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaboration; LewingtonSWhitlockGBlood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deathsLancet200737096021829183918061058
   PubMed Web of Science ®Google Scholar
• SchatzIJMasakiKYanoKCholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort studyLancet2001358927935135511502313
   PubMed Web of Science ®Google Scholar
• AfilaloJDuqueGSteeleRStatins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysisJ Am Coll Cardiol2008511374518174034
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJGLichtensteinAH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risks in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation201412925 Suppl 2S1S4524222016
   PubMed Web of Science ®Google Scholar
• CleggAYoungJLliffeSFrailty in elderly peopleLancet2013381986875276223395245
   PubMed Web of Science ®Google Scholar
• Livalo^® (pitavastatin) [package insert]Montgomery, ALKowa Pharmaceuticals America, Inc2013
   Google Scholar
• BakerWLDattaRPitavastatin: a New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor for the Treatment of HyperlipidemiaAdv Ther2011281132721170619
   PubMed Web of Science ®Google Scholar
• AokiTNishimuraHNagakawaSPharmacologic profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductaseArzneimittelforschung19974789049099296275
   PubMed Web of Science ®Google Scholar
• MorikawaSUmetaniMNakagawaSRelative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMGCoA reductase inhibitors in cultured human cellsJ Atheroscler Thromb20007313814411480454
   PubMedGoogle Scholar
• SuzukiHAokiTTamakiTHypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigsAtherosclerosis1999146225927010532682
   PubMed Web of Science ®Google Scholar
• SaitoYCritical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goalsVasc Health Risk Manag2009592193619997573
   PubMedGoogle Scholar
• AlagonaPPitavastatin: evidence for its place in treatment of hypercholesterolemiaCore Evid201059110521468365
   PubMedGoogle Scholar
• ShimadaSFujinoHHojimaJMoriyasuMKojimaJUptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytesDrug Metab Pharmacokinet200318424525115618742
   PubMedGoogle Scholar
• HiranoMMaedaKShitaraYSugiyamaYContribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humansJ Pharmacol Exp Ther2004311113914615159445
   PubMed Web of Science ®Google Scholar
• HasanumaTNakamuraMYajiTThe drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporineJ Clin Therap Med2003194381389
   Google Scholar
• MorganRECampbellSEYuCYSponsellerCAMusterHAComparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjectsJ Cardiovasc Pharmacol2012601424822472908
   PubMed Web of Science ®Google Scholar
• HuiCKCheungMYLauGKPharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosisBr J Clin Pharmacol200459329129715752374
   PubMed Web of Science ®Google Scholar
• ErikssonMBudinskiDHounslowNComparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trialAdv Ther201128981182321874538
   PubMed Web of Science ®Google Scholar
• SponsellerCAMorganREKryzhanovskiVACampbellSEDavidsonMHComparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a phase IV, prospective, US, multicenter, randomized, double-blind, superiority trialClin Ther20143681211122224998014
   PubMed Web of Science ®Google Scholar
• StenderSBudinskiDGoshoMHounslowNPitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolemia or combined (mixed) dyslipidemiaEur J Prev Cardiol2013201405322679249
   PubMed Web of Science ®Google Scholar
• StenderSBudinskiDHounslowNPitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolemia or combined (mixed) dyslipidaemiaEur J Prev Cardiol2013201293922345687
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationClinical Review PitavastatinCenter for Drug Evaluation and Research2009 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000_MedR_P1.pdfAccessed January 29, 2015
   Google Scholar
• WaritaSKawasakiMTanakaREffect of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients. A prospective study of 2-years’ follow-upCirc J201276122755276222878405
   PubMed Web of Science ®Google Scholar
• OseLBudinskiDHounslowNArnesonVComparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemiaCurr Med Res Opin200925112755276519785568
   PubMed Web of Science ®Google Scholar
• OseLBudinskiDHounslowNArnesonVLong-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemiaAtherosclerosis2010210120220820080236
   PubMed Web of Science ®Google Scholar
• GumprechtJGoshoMBudinskiDHounslowNComparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemiaDiabetes Obes Metab20111311047105521812889
   PubMed Web of Science ®Google Scholar
• Rodriquez ArroyoLADiaz RodriquezAPinto SataXCoca PaverasARius TaruellaJEffectivity and satisfaction with the treatment of dyslipidemia with pitavastatin. Multicentric, descriptive, post authorized and observational study (REINA study)Clin Investig Arterioscler2014265205217 Spanish
   Google Scholar
• BlasettoJWSteinEABrownWVChitraRRazaAEfficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groupsAm J Cardiol2003915A3C10C
   Web of Science ®Google Scholar
• HarleyCRGandhiSBlasettoJLow-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practiceAm J Geriatr Pharmacother20075318519417996658
   PubMedGoogle Scholar
• DeedwaniaPStonePHBairey MerzCNEffects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)Circulation2007115670070717283260
   PubMed Web of Science ®Google Scholar
• DavignonJPleiotropic effects of pitavastatinBr J Clin Pharmacol2011734S18S35
   Web of Science ®Google Scholar
• RichardonKSchoenMFrenchBStatins and cognitive function: a systematic reviewAnn Intern Med20131591068869724247674
   PubMed Web of Science ®Google Scholar
• Rojas-FernandezCHGoldsteinLBLeveyAITaylorBABittnerVThe National Lipid Association’s Safety Task ForceAn assessment by the Statin Cognitive Safety Task Force: 2014 updateJ Clin Lipidol201483 SupplS5S1624793442
   PubMed Web of Science ®Google Scholar
• MacedoAFTaylorFCCasasJPAdlerAPrieto-MerinoDEbrahimSUnintended effects of statins from observational studies in the general population: systematic review and meta-analysisBMC Med2014225124655568
   PubMed Web of Science ®Google Scholar
• RosensenRSBakerSKJacobsonTAKopeckySLParkerBAThe National Lipid Association’s Muscle Safety Expert PanelAn assessment by the Statin Muscle Safety Task Force: 2014 updateJ Clin Lipidol201483 SupplS58S7124793443
   PubMed Web of Science ®Google Scholar
• BaysHCohenDEChalasaniNHarrisonSAThe National Lipid Association’s Statin Safety Task ForceAn assessment by the Statin Liver Safety Task Force: 2014 updateJ Clin Lipidol201483 SupplS47S5724793441
   PubMed Web of Science ®Google Scholar